Product Images Gabapentin

Gabapentin is a USP capsule medication manufactured by Ascent Pharmaceuticals, Inc. for Cipla USA, Inc. The package contains 100 capsules with each capsule containing 100mg of gabapentin. The medication guide should be dispensed by a pharmacist along with the medication. See the package insert for detailed prescription information. The capsules should be stored at room temperature between 20° to 25°C. The manufacturer's address is given as Central Islip, NY 11722, while the medication is manufactured for Cipla USA, Inc., located at 10 Independence Boulevard, Suite 300, Warren, NJ 07059. The text includes a GTIN code but is not readable.*

Gabapentin Capsules, USP with NDC code 69097-813-07 is a prescription medication manufactured by InvaGen Pharmaceuticals, Inc. for Cipla USA, Inc. Each bottle contains 100 capsules of 100 mg gabapentin (USP). The medication guide should be enclosed for the pharmacist to distribute. Dosage and use information can be found in the package insert. It should be stored between 20°C to 25°C (68°F to 77°F).*

This is a prescription drug with the National Drug Code 69097-943-07. Each capsule contains 300 mg of gabapentin, and it should be stored at 20° to 25°C (68° to 77°F). The drug is manufactured by Ascent Pharmaceuticals and dispensed by FHARMACIST. It is also manufactured for Cipla USA, Inc., and includes a medication guide. Refer to the package insert for full prescribing information.*

Each capsule of the drug contains 300mg of gabapentin. It is a prescription drug and should be stored at 20-25°C. The drug is manufactured by InvaGen Pharmaceuticals, Inc., and dispensed with an attached medication guide. Cipla USA, Inc. has manufactured the drug's capsules.*

NDC 69097-814-07 Rowmy each capsule contains 300mg of Gabapentin, USP. The capsules should be stored at 20-25°C (68-77°F). It is a medication used to treat seizures, neuropathic pain, and hot flashes. Manufactured by Cipla USA, the pharmaceutical is for oral administration only. Pharmacists are advised to dispense the capsules with an attached medication guide.*

This is a prescription drug with the NDC code 69097-814-07, containing 300 mg gabapentin. The drug is available in the form of capsules and is stored at a temperature range of 20°C to 25°C. The medication guide should be attached before dispensing. It is manufactured by Cipla USA, Inc. The GTIN number and SN number are mentioned. The drug is distributed by InvaGen Pharmaceuticals, Inc., a subsidiary of Cipla Ltd. The lot number is B0.*

NDC 69097-81507 is a prescription-only medication in capsule form containing 400mg. Dosage and usage instructions can be found in the package insert. The capsules are to be stored at a temperature between 20°C to 25°C (68°F to 77°F). The manufacturer is Ascent Pharmaceuticals, Inc. and it is distributed by Cipla USA, Inc. The medication comes in 100 capsules per bottle. The GTIN and SN codes are also listed.*

Each capsule of this medication contains 400mg of gabapentin, a prescription drug indicated for several conditions such as neuropathic pain and epilepsy. The recommended dosage and usage instructions can be found in the package insert. It is to be stored at room temperature, between 20-25°C (68-77°F). The medication is manufactured by Invagen Pharmaceuticals, a subsidiary of Cipla Ltd., and dispensed with an attached medication guide. This bottle contains 100 capsules, and it was manufactured for Cipla USA, Inc. located in Warren, NJ. Rev. 03/2020.*

This is a dosage table for the medication gabapentin based on the patient's renal function. The table provides the total daily dose range for patients with different levels of creatinine clearance, measured in mL/min. The suggested dosing regimens vary from 300TID to 1,200TID for patients with creatinine clearance greater than or equal to 60mL/min, to 100QD to 700QD for those with a clearance of 15 to 59 mL/min. For patients on hemodialysis, the maintenance doses are based on estimates of creatinine clearance, and a supplemental dose is given after each 4 hours of hemodialysis. The table also includes dosage recommendations for patients with a creatinine clearance of less than 15 mL/min. The text provides additional information about the estimation of creatinine clearance.*

This text provides a risk assessment for antiepileptic drugs, with a breakdown by indication of epilepsy, psychiatric, and other conditions. It includes data on the incidence of events in both placebo patients and drug patients, as well as the relative risk and risk difference between the two groups.*

This is a table that shows the adverse reactions found in pooled placebo-controlled trials in Postherpetic neuralgia. The table compares Gabapentin, with 336 patients, and Placebo with 227. The adverse reactions are classified by body system or general body area, such as Body as a Whole, Digestive System, Metabolic and Nutritonal Disorders, Nervous System, Respiratory System, and Special Senses. There are several specific symptoms under each classification, along with the percentage of patients affected by that symptom. Some of the most frequent symptoms are asthenia, infection, accidental injury, diarrhea, dry mouth, dizziness, and abnormal thinking.*

This is a table displaying adverse reactions in pooled placebo-controlled Add-on trials in epilepsy patients over 12 years of age who were administered Gabapentin® and Placebo. The percentages of occurrence of each adverse reaction are mentioned. The reactions are listed under various body systems such as Body As A Whole, Cardiovascular, Nervous System, Respiratory system, and more. One of the Special Senses reactions, Amblyopia, is described as blurred vision.*

This is a table showing the adverse reactions reported in pediatric epilepsy patients aged 3 to 12 years during a placebo-controlled add-on trial of Gabapentin. The table shows the percentage of adverse reactions observed in patients receiving Gabapentin compared to those receiving a placebo. The adverse reactions reported include body aches, viral infections, fever, increased weight, fatigue, nausea, vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infections. It is noteworthy that patients were also receiving background antiepileptic drug therapy.*

This text seems to be a figure caption presenting data from controlled studies on PHN (postherpetic neuralgia) patients. The figure shows the percentage of patients who experienced a reduction in pain score of greater than 50% at the end of the studies. "p<0.001" is a statistical significance index. The caption also mentions three drug doses (GEP 3600, GBP 1800, GBP 2400). No further information is available from the text.*